 View / print now (4,239kb) |
China's pharmaceuticals market is forecast to become the world's firth largest by 2010 - and the largest by 2050. Yet despite greater market access following China's entry into the World Trade Organisation (WTO), multinational investors continue to face a range of obstacles, many of which stem from the legacy of central planning of the industry. These include complex distribution, under-developed retail options, intellectual property infringements and pricing controls and pressures. At the same time, the continuing reliance of leading domestic companies on generic drugs has prevented the emergence of Chinese brands. This report examines the key issues affecting investment in one of the world's fastest-growing pharmaceutical markets.
This publication is a follow on report from the "China - Prescription for Growth" series.
Publications Search Page
